Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).

Therapeutic indications:

Sofosvel is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infections

  • With or without cirrhosis or with compensated cirrhosis
  • With decompensated cirrhosis for use in combination with Ribavirin

Product Name         :      Sofosvel

Generic Name         :  Sofosbuvir 400mg + Velpatasvir 100 mg

Formulation            : Solid dosage form(Tablet)

Available pack size  :   1×6’s

Strengths                  : 400mg+ 100mg